Abstracts tagged "Outcome measures"

Abstract Number: 1492 • ACR Convergence 2024
Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE
Edward Vital¹, Richard Furie², Eric Morand³, Ian Bruce⁴, Jacob Knagenhjelm⁵ and Catharina Lindholm⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, ²Northwell Health, Manhasset, NY, ³School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ⁴Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁵BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁶BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…
Abstract Number: 1746 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Rheumatoid Arthritis
Andreas Kerschbaumer¹, Marlene Steiner², Pascale Pruckner¹, Josef Smolen³ and Daniel Aletaha⁴, ¹Medical University of Vienna, Vienna, Wien, Austria, ²Medical University Vienna, Vienna, Wien, Austria, ³Medical University of Vienna, Vienna, Austria, ⁴Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Wien, Austria
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with rheumatoid arthritis (RA). Since the advent…
Abstract Number: 2215 • ACR Convergence 2024
Treat (Depression to Reach)-to-Target in Rheumatoid Arthritis
Ozun Bayindir Tsechelidis¹, Ricardo Sabido-Sauri², Ummugulsum Gazel², Seyyid Bilal Acikgoz³, Sylvia Sangwa⁴, Catherine Ivory⁵, Elliot Hepworth² and Sibel Aydin⁶, ¹Ottawa University, Ottawa, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³University of Ottawa, Rheumatology, Ottawa, ON, Canada, ⁴The Ottawa Hospital Research Institute, Ottawa, Canada, ⁵The Ottawa Hospital, Ottawa, ON, Canada, ⁶University of Ottawa - Ottawa, Ottawa, ON, Canada
Background/Purpose: Depression is a prevalent comorbidity in Rheumatoid Arthritis (RA), affecting up to 38.8% of individuals. Depression can profoundly affect physical well-being, including increased pain…
Abstract Number: 2410 • ACR Convergence 2024
A Novel Treatment Response Measure for SLE Clinical Trials (TRM-SLE): Selection of Domains and Candidate Measures
Kathryn Connelly¹, Rachel Koelmeyer¹, Darshini Ayton¹, Lavanya Rajagopala², Ambika Wahklu², John May³, Raychel Barallon⁴, Rangi Kandane-Rathnayake⁵, Laura Eades¹, kate Gregory¹ and Eric Morand⁶, and the TRM-SLE Taskforce, ¹Monash University, Melbourne, Victoria, Australia, ²Monash Health, Melbourne, Victoria, Australia, ³Monash Medical Centre, Richmond, Victoria, Australia, ⁴Monash Health, Clayton, Victoria, Australia, ⁵Monash University, Clayton, Victoria, Australia, ⁶School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia
Background/Purpose: The success of randomised controlled trials (RCTs) in SLE has been hampered by limitations of current outcome measures, contributing to negative or discordant trial…
Abstract Number: 0265 • ACR Convergence 2024
Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Dansoa Tabi-Amponsah¹, Michael Doherty², Aliya Sarmanova³, Weiya Zhang², Sarah Stewart⁴, William Taylor⁵, Lisa Stamp⁶ and Nicola Dalbeth⁷, ¹The University of Auckland, Auckland, New Zealand, ²Academic Rheumatology, School of Medicine, University of Nottingham; Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom, ³Roche Diagnostics International, Clinical Development and Medical Affairs, Nottingham, England, United Kingdom, ⁴Auckland University of Technology, Auckland, New Zealand, ⁵The University of Otago, Wellington, Wellington, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand
Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…
Abstract Number: 0531 • ACR Convergence 2024
Costs and Clinical Outcomes of the Rheumatoid Arthritis Medication Tapering Cohort
Sama Hajizadeh¹, Tyson Barrett², Yue Yin³ and Dr Tarun Sharma⁴, ¹Allegheny Health Network, Pittsburgh, ²Enterprise Data and Analytics, Highmark Health, Pittsburgh, ³Allegheny-Singer Research Institute, Allegheny Health Network, Pittsburgh, ⁴West Penn Hospital, Pittsburgh, PA
Background/Purpose: Existing American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) guidelines regarding medication tapering in patients with rheumatoid arthritis (RA)…
Abstract Number: 0644 • ACR Convergence 2024
Scoping Literature Review to Identify Candidate Domains for the SLE OMERACT Core Outcome Set
Wils Nielsen¹, Fadi Kharouf², Carolina Munoz-Grajales³, Aarabi Thayaparan⁴, Melanie Anderson⁵, Lee Simon⁶, Maya Desai⁷, Ioannis Parodis⁸, Alfred Kim⁹, Yvonne Enman¹⁰, Kathleen Bingham¹¹, Dennisse Bonilla¹¹, Julian Thumboo¹², Marta Mosca¹³, Martin Aringer¹⁴, Eric Morand¹⁵, Ian Bruce¹⁶, Vibeke Strand¹⁷ and Zahi Touma⁴, ¹University of Toronto, Markham, ON, Canada, ²University Health Network and University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ³UHN/TWH, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁶SDG LLC, West Newton, MA, ⁷Ontario College of Art and Design University, Toronto, ON, Canada, ⁸Karolinska Institutet, Karolinska University Hospital; Örebro University, Solna, Sweden, ⁹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹University Health Network, Toronto, ON, Canada, ¹²Singapore General Hospital, Singapore, Singapore, ¹³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, ¹⁴University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany, ¹⁵School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, ¹⁶Centre for Musculoskeletal Research, Division of Musculoskeletal and Dermatological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, United Kingdom, ¹⁷Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The Outcome Measures in Rheumatology (OMERACT) Systemic Lupus Erythematosus (SLE) Working Group was re-established in 2018 to update the SLE Core Outcome Set (COS)…
Abstract Number: 0818 • ACR Convergence 2024
Defining BASDAI Cut-offs for Disease Activity States in Axial Spondylarthritis – Results from the EuroSpA Collaboration
Stylianos Georgiadis¹, Lykke Oernbjerg¹, Brigitte Michelsen², Tore K. Kvien³, Simon Horskjær Rasmussen⁴, Jakub Závada⁵, Kristýna Bubová⁶, Bente Glintborg⁷, Anne Gitte Loft⁸, Ana Maria Rodrigues⁹, Maria Jose Santos¹⁰, Adrian Ciurea¹¹, Michael Nissen¹², Laura Kuusalo¹³, Jarno Rutanen¹⁴, Ziga Rotar¹⁵, Katja Perdan-Pikmajer¹⁵, Bjorn Gudbjornsson¹⁶, Olafur Palsson¹⁷, Daniela DiGuiseppe¹⁸, Mikkel Ostergaard¹⁹ and Merete Hetland²⁰, ¹Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ²Rigshospitalet Glostrup, Diakonhjemmet Hospital and Sørlandet Hospital, Copenhagen, Denmark, ³Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ⁴Rigshospitalet Glostrup, Glostrup, Denmark, ⁵Institute of Rheumatology and Charles University, Praha, Czech Republic, ⁶Institute of Rheumatology and Charles University, Prague, Czech Republic, ⁷DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁸Aarhus University Hospital and Aarhus University, Horsens, Denmark, ⁹Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁰Hospital Garcia de Orta and Centro Académico de Medicina de Lisboa, Lisboa, Portugal, ¹¹University Hospital Zurich, Zürich, Switzerland, ¹²Geneva University Hospital, Geneva, Switzerland, ¹³University of Turku and Turku University Hospital, Turku, Finland, ¹⁴Tampere University Hospital, Tampere, Finland, ¹⁵University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁶Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁷University of Iceland and Skåne University Hospital, Reykjavik, Iceland, ¹⁸Karolinska Institutet, Stockholm, ¹⁹Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²⁰Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: While the Axial Spondyloarthritis Disease Activity Score based on C-reactive protein (ASDAS) is recommended for assessment of disease activity in patients with axial spondyloarthritis…
Abstract Number: 1137 • ACR Convergence 2024
Deucravacitinib, an Oral,Selective,Allosteric Tyrosine Kinase 2 Inhibitor, in Patients WithModerate to Severe Scalp Psoriasis: Efficacy and Safety Results of a Phase 3b/4, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial (PSORIATYK SCALP)
Kristina Callis Duffin¹, Christopher E. M. Griffiths², Matthias Hoffmann³, Andrew Blauvelt⁴, Eugene Balagula⁵, Andrew Napoli⁵, Ying-Ming Jou⁵, Rachel Dyme⁵, Virginia Hala⁵, andreas pinter⁶ and Mark Lebwohl⁷, ¹University of Utah, Salt Lake City, ²Dermatology Centre, University of Manchester, Manchester, and King’s College Hospital and King’s College London, London, United Kingdom, ³Private Practice, Witten, Germany, ⁴Oregon Medical Research Center, Portland, OR, ⁵Bristol Myers Squibb, Princeton, ⁶University Hospital of the Goethe University, Frankfurt am Main, Frankfurt, Germany, ⁷Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in the US, EU, and other countries for treatment of adults with…
Abstract Number: 1498 • ACR Convergence 2024
Gender Disparities in Clinical Manifestations and Outcomes of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mazen Allouni¹, Muhammad Shamim², Krista Topalsky³ and Omer Pamuk⁴, ¹Case Western Reserve, University Hospitals, Cleveland Medical Center, Cleveland, OH, ²University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ³University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: The clinical manifestations and outcomes of systemic lupus erythematosus (SLE) reveal notable gender differences, which may impact treatment strategies and patient outcomes. This meta-analysis…
Abstract Number: 1882 • ACR Convergence 2024
30-Day Readmission Among Patients with Rheumatoid Arthritis and Their Independent Predictors: Insights from National Readmission Database
Shobhit Piplani¹, Priyanshu Jain², Vladimir Jelic³, Clement Tagoe⁴ and Beverly Johnson⁵, ¹Jacobi Medical Center/North Central Bronx Albert Einstein College of Medicine NYC Health and Hospitals, Bronx, NY, ²Jawaharlal Nehru Medical College, Belgaum, Karnataka, India, Bronx, NY, ³Jacobi Medical Center/North Central Bronx, Bronx, NY, ⁴Albert Einstein College of Medicine, FRESH MEADOWS, NY, ⁵Albert Einstein College of Medicine, New York, NY
Background/Purpose: Rheumatoid Arthirits (RA) is associated with heightened morbidity, diminished quality of life, and increased healthcare expenses. This research aims to bridge this gap by…
Abstract Number: 2218 • ACR Convergence 2024
Association Between Frailty and Peri-Operative Inpatient Adverse Outcomes Among Patients with and Without Rheumatoid Arthritis
Ali Yazdanyar¹, Joshua Baker², Katherine Wysham³ and Michael Ward⁴, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴NIH, Bethesda, MD
Background/Purpose: Frailty is a state reflecting a reduced physiologic reserve. There is accumulating literature on the prevalence and clinical significance of frailty in Rheumatoid Arthritis…
Abstract Number: 2466 • ACR Convergence 2024
Ranked Composite Important Difference (RCID) Scores in Patients with Diffuse Cutaneous Systemic Sclerosis and Interstitial Lung Disease
Francesco Del Galdo¹, Lesley-Anne Bissell², Rozeta Simonovska³ and Margarida Alves⁴, ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁴Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany
Background/Purpose: The ACR Composite Response Index in diffuse cutaneous Systemic Sclerosis (CRISS) was developed to measure the probability of improvement in response to treatment in…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…
Abstract Number: 0541 • ACR Convergence 2024
Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Clementina López Medina¹, Anna Molto², Dafne Capelusnik³, Philippe Carron⁴, Casper Webers⁵, Filip Van den Bosch⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴UZ Gent, Gent, Belgium, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Understanding the best-performing disease activity measure and response criterion in peripheral spondyloarthritis (pSpA) is crucial for the development of future meaningful clinical studies. The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].